Patients with type 2 diabetes prescribed GLP-1 RAs show a reduced risk of legal blindness compared with those not receiving the therapy.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results